- Home
- WEA vs CGTX Comparison
WEA vs CGTX Comparison
Compare WEA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | CGTX |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 94.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WEA | CGTX |
|---|---|---|
| Price | $10.75 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 30.0K | ★ 609.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $0.22 |
| 52 Week High | $11.44 | $3.83 |
Technical Indicators
Market Signals| Indicator | WEA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 51.98 |
| Support Level | $10.65 | $1.00 |
| Resistance Level | $10.87 | $1.19 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 32.58 | 75.00 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.